Nasofan (Fluticasone Propionate)

Fluticasone Propionate, the active ingredient in Nasofan, is a corticosteroid (glucocorticoid) presented as a nasal spray for nasal use. It treats allergic inflammation of the nasal passages in adults and children with allergic rhinitis or nasal polyps.

GNH USA supplies Nasofan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Fluticasone Propionate nasal spray acts on inflammatory pathways of the nasal mucosa to relieve allergic symptoms. - Allergic rhinitis: reduces nasal congestion, itching, sneezing and rhinorrhea. - Seasonal allergic rhinitis: controls symptoms triggered by pollen or other seasonal allergens. - Perennial allergic rhinitis: provides year‑round relief from indoor allergen‑induced symptoms. - Nasal polyps: helps shrink polyps and improves nasal airflow.

Fluticasone propionate may cause local and systemic adverse reactions.

Common Side Effects: - Nasal irritation or burning sensation. - Epistaxis (nosebleeds). - Headache. - Sore throat. - Cough. - Altered taste or oral dryness.

Serious or Rare Side Effects: - Adrenal suppression with prolonged high‑dose use. - Glaucoma or cataract formation. - Severe nasal septum perforation. - Opportunistic fungal infection of the nasal cavity. - Systemic immunosuppression leading to increased infection risk. - Hypersensitivity reactions including angioedema.

Before using Nasofan, consider the following safety measures. - Pregnancy: consult a healthcare professional before use. - Breastfeeding: discuss potential risks with a physician. - Pediatric use: follow age‑appropriate dosing guidelines. - Abrupt discontinuation: taper if long‑term therapy is stopped to avoid rebound inflammation. - Ocular monitoring: watch for signs of glaucoma or cataracts. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Fluticasone propionate can interact with other medicines; awareness helps minimize risk.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic exposure. - Live vaccines: reduced efficacy and potential infection risk.

Moderate Interactions (Monitor Closely): - Systemic corticosteroids: additive glucocorticoid effects. - Antifungal agents (e.g., fluconazole): may raise fluticasone levels. - Protease inhibitors (e.g., ritonavir): potential increase in exposure.